menu
    • menu
    [{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"VET2-L2","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KaliVir Immunotherapeutics","amount2":0.63,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.63,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Astellas","highestDevelopmentStatusID":"4","companyTruncated":"KaliVir Immunotherapeutics \/ Astellas"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VET-ROG1","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"KaliVir Immunotherapeutics \/ Roche"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ KaliVir Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KaliVir Immunotherapeutics \/ KaliVir Immunotherapeutics"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ASP1012","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KaliVir Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KaliVir Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KaliVir Immunotherapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by KaliVir Immunotherapeutics

    Menu

    KaliVir Immunotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VET3-TGI,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KaliVir Doses First Patient in Trial of VET3-TGI For Advanced Solid Tumors

                            Details : VET3-TGI is an oncolytic immunotherapy, given intratumoraly, that acts as a TGF beta-1 inhibitor & IL-12 stimulator, is being studied in combination with pembrolizumab for treating solid tumors.

                            Brand Name : VET3-TGI

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 08, 2024

                            Lead Product(s) : VET3-TGI,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VET3-TGI,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KaliVir Immunotherapeutics Gets FDA Clearance for VET3-TGI Oncolytic Immunotherapy

                            Details : VET3-TGI is an oncolytic immunotherapy, given intratumoraly, that acts as a TGF beta-1 inhibitor & IL-12 stimulator, is being studied in combination with pembrolizumab for treating solid tumors.

                            Brand Name : VET3-TGI

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : VET3-TGI,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASP1012

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Vi...

                            Details : ASP1012 (formerly named VET2-L2) is a systemic oncolytic vaccinia virus therapy in which the virus is delivered intravenously and expresses Leptin-IL2 fusion protein as a therapeutic payload. The trial is expected to begin in Q1 2024.

                            Brand Name : ASP1012

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : ASP1012

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : SIGA Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

                            Details : TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 15, 2022

                            Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : SIGA Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VET-ROG1

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Vir...

                            Details : Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company's VETTM platform, including VET-ROG1 expressing Roche proprietary therapeutic transgenes.

                            Brand Name : VET-ROG1

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 23, 2022

                            Lead Product(s) : VET-ROG1

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KaliVir Immunotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VET2-L2

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Astellas Pharma

                            Deal Size : $634.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            KaliVir Immunotherapeutics and Astellas Ink Licensing Agreement for Development and Commercialization of VET2-...

                            Details : Under the terms of the agreement, Astellas will pay to KaliVir up to US$56 million in the form of an upfront payment and other payments to support research and preclinical activities related to VET2-L2 and the Second Product.

                            Brand Name : VET2-L2

                            Molecule Type : Large molecule

                            Upfront Cash : $56.0 million

                            December 07, 2020

                            Lead Product(s) : VET2-L2

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Astellas Pharma

                            Deal Size : $634.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth